Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B

NCT05540860 is registered in ClinicalTrials.gov with Edgewise Therapeutics, Inc. as lead sponsor.

NCT NCT05540860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05540860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B
Lead sponsor
Edgewise Therapeutics, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 24, 2022
Completion date
January 31, 2027
Enrollment
76 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy